Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

ClinicalTrials.gov ID: NCT07680790

Public ClinicalTrials.gov record NCT07680790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

Study identification

NCT ID: NCT07680790
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 850 participants

Conditions and interventions

Conditions

Non-Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 8, 2026 (Actual)
Primary completion: Dec 30, 2031 (Estimated)
Completion: Dec 30, 2031 (Estimated)
Last update posted: Oct 8, 2026

2026 – 2031

United States locations

U.S. sites: 35
U.S. states: 22
U.S. cities: 34

Facility	City	State	ZIP	Site status
Local Institution - 0212	Beverly Hills	California	90211	Not yet recruiting
Local Institution - 0504	Fullerton	California	92835	Not yet recruiting
Local Institution - 0357	La Jolla	California	92093	Not yet recruiting
Local Institution - 0520	Boulder	Colorado	80304	Not yet recruiting
Local Institution - 0527	Fort Myers	Florida	33901	Not yet recruiting
Local Institution - 0366	Orlando	Florida	32806	Not yet recruiting
Cancer Care Centers of Brevard - Rockledge	Palm Bay	Florida	32901	Recruiting
Local Institution - 0526	St. Petersburg	Florida	33701	Not yet recruiting
Local Institution - 0524	West Palm Beach	Florida	33401	Not yet recruiting
Local Institution - 0207	Ottawa	Illinois	61350	Not yet recruiting
Local Institution - 0503	Baltimore	Maryland	21202	Not yet recruiting
Local Institution - 0523	Silver Spring	Maryland	20904	Not yet recruiting
Local Institution - 0521	Edina	Minnesota	55435-2150	Not yet recruiting
Local Institution - 0364	Saint Paul	Minnesota	55102	Not yet recruiting
Local Institution - 0403	St Louis	Missouri	63110	Not yet recruiting
Local Institution - 0402	Omaha	Nebraska	68198	Not yet recruiting
Local Institution - 0290	Lebanon	New Hampshire	03756	Not yet recruiting
Local Institution - 0183	New Brunswick	New Jersey	08901	Not yet recruiting
Local Institution - 0153	New York	New York	10021	Not yet recruiting
Local Institution - 0157	The Bronx	New York	10461	Not yet recruiting
Local Institution - 0385	Charlotte	North Carolina	28204	Not yet recruiting
Local Institution - 0438	Sandusky	Ohio	44870	Not yet recruiting
Local Institution - 0404	Portland	Oregon	97213	Not yet recruiting
Local Institution - 0487	Easton	Pennsylvania	18045	Not yet recruiting
Local Institution - 0200	Sioux Falls	South Dakota	57104	Not yet recruiting
Local Institution - 0199	Memphis	Tennessee	38120	Not yet recruiting
Texas Oncology	Beaumont	Texas	77702	Recruiting
Local Institution - 0525	Dallas	Texas	75246	Not yet recruiting
Texas Oncology - San Antonio	San Antonio	Texas	78217	Recruiting
Local Institution - 0411	Salt Lake City	Utah	84112	Not yet recruiting
Local Institution - 0165	Fairfax	Virginia	22031	Not yet recruiting
Local Institution - 0530	Fairfax	Virginia	22031	Not yet recruiting
Shenandoah Oncology, P.C. (Shenandoah Oncology Associates, P.C.)	Winchester	Virginia	22601	Recruiting
Local Institution - 0283	Seattle	Washington	98104	Not yet recruiting
Local Institution - 0502	Morgantown	West Virginia	26505	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 166 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07680790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2026 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07680790 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →